Literature DB >> 24160849

Large B-cell lymphomas in adolescents and young adults in comparison to adult patients: a matched-control analysis in 55 patients.

Diane Coso1, Sylvain Garciaz, Benjamin Esterni, Florence Broussais-Guillaumot, Vadim Ivanov, Thérèse Aurran-Schleinitz, Jean-Marc Schiano, Anne-Marie Stoppa, Bruno Chetaille, Didier Blaise, Norbert Vey, Réda Bouabdallah.   

Abstract

The aim of our study was to assess whether large B-cell lymphoma (LBCL) in adolescents and young adults (AYA) should be considered as a clinocopathological entity, and to evaluate the prognostic value of age. Fifty-five patients aged > 15-30 years were fully matched to 365 adult patients aged 31-65 years. We found a high incidence of primary mediastinal thymic LBCL subtype (33% vs. 5%), while histological transformation was rare (2% vs. 14%). LBCL in AYA presented with a bulky mediastinal mass (51% vs. 21%), and the lactate dehydrogenase (LDH) value was significantly higher (73% vs. 54%). The complete response rate to chemotherapy was similar in the two groups. Five-year overall survival (OS) and event-free survival (EFS) of AYA were 73% and 68%, respectively. The matched-control analysis showed no difference for either OS or EFS. LBCL in AYA presents with some critical features which differ from those of older adults. However, the outcome is equivalent to that observed in older patients.

Entities:  

Keywords:  Large cell lymphoma; adolescents; young adults

Mesh:

Year:  2014        PMID: 24160849     DOI: 10.3109/10428194.2013.858814

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  The better outcomes of diffuse large B-cell lymphoma in adolescents and young adults.

Authors:  Junnan Wang; Fengshang Yan; Yiran Wang
Journal:  Int J Hematol       Date:  2018-07-14       Impact factor: 2.490

2.  Clinical characteristics and outcomes of diffuse large B-cell lymphoma in adolescents and young adults.

Authors:  Yasuhiro Suzuki; Takahiro Yano; Youko Suehiro; Hiromi Iwasaki; Michihiro Hidaka; Maki Otsuka; Kazutaka Sunami; Nobumasa Inoue; Morio Sawamura; Takuo Ito; Hiroatsu Iida; Hirokazu Nagai
Journal:  Int J Hematol       Date:  2018-03-31       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.